盐酸缬更昔洛韦片要怎么购买？

The tablet, developed by Roche, is the first oral anti-cytomegalovirus infection drug for the treatment of retinitis. Valganciclovir hydrochloride is also approved for the prevention of cytomegalovirus infection after bone marrow, heart, liver, lung and other transplant surgeries. The general course of treatment is 3-6 months. CMV retinitis is a common syndrome that threatens the vision of AIDS patients and bone marrow and organ (liver, kidney, heart, etc.) transplant patients. Ganciclovir has good efficacy in treating cytomegalovirus infection, but its oral bioavailability is very low (6%~9%) and it can only be injected intravenously. CMV infection usually requires long-term maintenance treatment after induction therapy. Intravenous injection is used for long-term treatment, which is inconvenient and difficult for patients to accept. Valganciclovir hydrochloride is the prodrug of ganciclovir. Oral administration can achieve the efficacy of injected ganciclovir and is suitable for long-term treatment of cytomegalovirus infection.

How to buy Valganciclovir Hydrochloride Tablets?

Valganciclovir hydrochloride tablets (Valganciclovir) are already on the market in China and can be purchased by patients in large hospitals with a prescription. However, the price is extremely high, at US$2,250 per box, which is not as cost-effective as the US$750 of Valganciclovir hydrochloride tablets in India. Patients can obtain it through domestic professional overseas medical service institutions.

When tablets are used to prevent CMV infection in adult patients after organ transplantation, the recommended dose for kidney transplant patients is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 200 days after transplantation. For patients who have received a solid organ transplant other than a kidney, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation. Pregnant and lactating women: Due to the rapid and large-scale conversion of valganciclovir into ganciclovir, studies on its reproductive toxicity have not been repeated. In animal experiments, ganciclovir caused reduced fertility and teratogenic effects. It is recommended that women of childbearing potential use effective contraceptive measures during treatment. Male patients are advised to use barrier contraception during treatment with valganciclovir hydrochloride tablets and for at least 90 days after discontinuation of treatment.